Blog
RSS FeedPosted by Michael Wonder on 21 Apr 2020
Director of U.S. agency key to vaccine development leaves role suddenly amid coronavirus pandemic
21 April 2020 - Rick Bright, one of the nation’s leading vaccine development experts and the director of the Biomedical ...
Posted by Michael Wonder on 21 Apr 2020
Coronavirus puts big pharma’s IP regime to the test
21 April 2020 - “Chaotic” is how Jorge Contreras, a law professor at the University of Utah, describes a struggle ...
Posted by Michael Wonder on 21 Apr 2020
If pharma helps quench the COVID-19 pandemic, what will it want in return?
21 April 2020 - Make no mistake: the only long-term solution to the COVID-19 pandemic is a safe and effective ...
Posted by Michael Wonder on 20 Apr 2020
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalised COVID-19 patients
20 April 2020 - Novartis has reached an agreement with the US FDA to proceed with a Phase III clinical trial ...
Posted by Michael Wonder on 18 Apr 2020
NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options
17 April 2020 - The National Institutes of Health (NIH) and the Foundation for the NIH are bringing together more than ...
Posted by Michael Wonder on 17 Apr 2020
The coronavirus is mutating. What does that mean for a vaccine?
16 April 2020 - Around the world, hope for a return to normalcy is pinned on a vaccine, the “ultimate ...
Posted by Michael Wonder on 16 Apr 2020
Can the world find a good COVID-19 vaccine quickly enough?
16 April 2020 - And can it mass produce it fairly if it does? ...
Posted by Michael Wonder on 15 Apr 2020
Vaccine development becomes reality TV. Can it make viewers rethink pharma?
14 April 2020 - The pharmaceutical industry’s response to the novel coronavirus may not rescue its ailing reputation. But it ...
Posted by Michael Wonder on 15 Apr 2020
Product specific guidances for chloroquine phosphate and hydroxychloroquine sulphate
13 April 2020 - The FDA plays a critical role in protecting the United States from threats including emerging infectious ...
Posted by Michael Wonder on 14 Apr 2020
Vaccine development is a case of 'market failure'
13 April 2020 - Reliance on the private market to develop vaccines has failed, leaving us vulnerable to pandemics such as ...
Posted by Michael Wonder on 14 Apr 2020
Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review
13 April 2020 - The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 ...
Posted by Michael Wonder on 14 Apr 2020
COVID-19: world needs a global approach to fight: Bill Gates
12 April 2020 - Over the past few weeks, I’ve spoken to dozens of experts about COVID-19, and there’s clear ...
Posted by Michael Wonder on 08 Apr 2020
Pharmaceutical profits and public health are not incompatible
8 April 2020 - We need the capital and creativity of the private sector to take on the coronavirus. ...
Posted by Michael Wonder on 07 Apr 2020
Global plasma leaders collaborate to accelerate development of potential COVID-19 hyperimmune therapy
6 April 2020 - Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the ...
Posted by Michael Wonder on 02 Apr 2020
COVID-19 has changed how the world does science, together
1 April 2020 - Never before, scientists say, have so many of the world’s researchers focused so urgently on a single ...